
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
There is a great deal of work being done to minimize the duration of vaccine shortages; in the meantime, however, children may be left vulnerable to diseases we considered virtually wiped out.






